Literature DB >> 1100221

Clinical comparison of the nitrosoureas.

T H Wasserman, M Slavik, S K Carter.   

Abstract

The nitrosourea group of antitumor agents was developed by the Division of Cancer Treatment of the National Cancer Institute. Three nitrosoureas (BCNU, CCNU, MeCCNU) have undergone extensive clinical trials, and two of them (BCNU, CCNU) will soon become commercially available. This paper briefly considers the preclinical development of the nitrosoureas and provides an overview and comparison of the extensive clinical data. Information is given regarding any clinical differences. We discuss general conclusions drawn from the nitrosourea development.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1100221     DOI： 10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  15 in total

1.  Intra arterial chemotherapy with ACNU and radiotherapy in inoperable malignant gliomas.

Authors:  L Chauveinc; M T Sola-Martinez; M Martin-Duverneuil; J J Mazeron; T Faillot; P Cornu; L Capelle; J Y Delattre; M Poisson; F Baillet; J Chiras
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  An A,B,C,D of cancer chemotherapy.

Authors:  E Y Chan; R J Cohen
Journal:  West J Med       Date:  1979-06

3.  Renal effects of S10036 in man.

Authors:  G Deray; D Khayat; C Jacquiaud; J P Bizzari; R Bourbouze; L Musset; M C Jaudon; B Baumelou; C Jacquillat; C Jacobs
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Palliative and adjunctive measures in rectal cancer.

Authors:  A Fritsch; W Seidl; C Walzel; K Moser; R Schiessel
Journal:  World J Surg       Date:  1982-09       Impact factor: 3.352

5.  Intensive chemotherapy with autologous bone marrow rescue for recurrent malignant gliomas.

Authors:  K Nomura; T Watanabe; O Nakamura; M Ohira; S Shibui; K Takakura; Y Miki
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

Review 6.  Cancer chemotherapy: new developments and changing concepts.

Authors:  S K Carter
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

7.  Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study.

Authors:  R H Earhart; F M Muggia; F M Golomb
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth.

Authors:  Christine J Weydert; Yuping Zhang; Wenqing Sun; Trent A Waugh; Melissa L T Teoh; Kelly K Andringa; Nukhet Aykin-Burns; Douglas R Spitz; Brian J Smith; Larry W Oberley
Journal:  Free Radic Biol Med       Date:  2007-11-28       Impact factor: 7.376

9.  The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.

Authors:  B Drewinko; L Y Yang
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

10.  Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy.

Authors:  F Vega; L Davila; G Chatellier; J Chiras; F Fauchon; P Cornu; L Capelle; M Poisson; J Y Delattre
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.